Influenza-attributable mortality in Australians aged more than 50 years: a comparison of different modelling approaches

2009 ◽  
Vol 138 (6) ◽  
pp. 836-842 ◽  
Author(s):  
A. T. NEWALL ◽  
C. VIBOUD ◽  
J. G. WOOD
Keyword(s):  
Respiratory Syncytial Virus ◽  
Poisson Regression ◽  
Regression Models ◽  
Disease Burden ◽  
Temporal Patterns ◽  
Attributable Mortality ◽  
Syncytial Virus ◽  
Viral Surveillance ◽  
Death Data ◽  
Modelling Approaches

SUMMARYThis study aimed to compare systematically approaches to estimating influenza-attributable mortality in older Australians. Using monthly age-specific death data together with viral surveillance counts for influenza and respiratory syncytial virus, we explored two of the most frequently used methods of estimating excess influenza-attributable disease: Poisson and Serfling regression models. These approaches produced consistent age and temporal patterns in estimates of influenza-attributable mortality in older Australians but some variation in the magnitude of the disease burden. Of Australians aged >50 years, average annual estimated influenza-attributable deaths (all cause) ranged from 2314 to 3457 for the Serfling and Poisson regression models, respectively. The excess influenza-attributable disease burden was substantial under all approaches.

scholarly journals Considerations for a Respiratory Syncytial Virus Vaccine Targeting an Elderly Population

Vaccines ◽  
2021 ◽  
Vol 9 (6) ◽  
pp. 624
Author(s):  
Laura M. Stephens ◽  
Steven M. Varga
Keyword(s):  
Respiratory Syncytial Virus ◽  
Disease Burden ◽  
Elderly Population ◽  
Vaccine Development ◽  
The Elderly ◽  
The United States ◽  
Susceptible Population ◽  
Age Related ◽  
Syncytial Virus ◽  
Tract Infections

Respiratory syncytial virus (RSV) is most commonly associated with acute lower respiratory tract infections in infants and children. However, RSV also causes a high disease burden in the elderly that is often under recognized. Adults >65 years of age account for an estimated 80,000 RSV-associated hospitalizations and 14,000 deaths in the United States annually. RSV infection in aged individuals can result in more severe disease symptoms including pneumonia and bronchiolitis. Given the large disease burden caused by RSV in the aged, this population remains an important target for vaccine development. Aging results in lowered immune responsiveness characterized by impairments in both innate and adaptive immunity. This immune senescence poses a challenge when developing a vaccine targeting elderly individuals. An RSV vaccine tailored towards an elderly population will need to maximize the immune response elicited in order to overcome age-related defects in the immune system. In this article, we review the hurdles that must be overcome to successfully develop an RSV vaccine for use in the elderly, and discuss the vaccine candidates currently being tested in this highly susceptible population.

scholarly journals Approaches to use the WHO respiratory syncytial virus surveillance platform to estimate disease burden

2019 ◽  
Vol 14 (6) ◽  
pp. 615-621 ◽  
Author(s):  
Richard Pebody ◽  
Jocelyn Moyes ◽  
Siddhivinayak Hirve ◽  
Harry Campbell ◽  
Sandra Jackson ◽  
...  
Keyword(s):  
Respiratory Syncytial Virus ◽  
Disease Burden ◽  
Virus Surveillance ◽  
Syncytial Virus

Respiratory syncytial virus (RSV) disease in hospitalised adults in Europe with COPD: Impact of GOLD score on RSV disease burden

2018 ◽  
Author(s):  
Thomas Harrer ◽  
Florian Thalhammer ◽  
Odile Launay ◽  
Arnaud Cheret ◽  
Guy de la Rosa ◽  
...  
Keyword(s):  
Respiratory Syncytial Virus ◽  
Disease Burden ◽  
Syncytial Virus ◽  
Copd Impact

scholarly journals 2557. A Model to Estimate the Potential Impact of Immunizations on Respiratory Syncytial Virus (RSV) Disease Burden Among Infants in the United States

2018 ◽  
Vol 5 (suppl_1) ◽  
pp. S69-S70
Author(s):  
Gayle E Langley ◽  
Alexandra Wheatley ◽  
Bishwa Adhikari ◽  
Martin I Meltzer ◽  
Gabriel Rainisch
Keyword(s):  
United States ◽  
Respiratory Syncytial Virus ◽  
Disease Burden ◽  
The United States ◽  
Potential Impact ◽  
Syncytial Virus

scholarly journals Hospitalization Rate of Respiratory Syncytial Virus associated Acute Lower Respiratory Infection among Young Children in Suzhou, China, 2010-2014

2021 ◽  
Author(s):  
Shaolong Ren ◽  
Ting Shi ◽  
Wei Shan ◽  
Si Shen ◽  
Qinghui Chen ◽  
...  
Keyword(s):  
Respiratory Syncytial Virus ◽  
Young Children ◽  
Respiratory Infection ◽  
Disease Burden ◽  
Estimation Method ◽  
Hospitalization Rate ◽  
Acute Lower Respiratory Infection ◽  
Lower Respiratory Infection ◽  
Treatment Data ◽  
Syncytial Virus

Background: Data on disease burden of respiratory syncytial virus (RSV) associated acute lower respiratory infection (ALRI) among young children are limited in China. This study aimed to estimate the hospitalization rate of RSV-associated ALRI (RSV-ALRI) among children aged 0~59 months in Suzhou, China. Methods: We retrospectively identified all hospitalized ALRI children aged 0~59 months in Suzhou University Affiliated Children’s Hospital during January 2010 to December 2014. Detailed diagnosis and treatment data were collected by individual medical chart review. Referring to WHO influenza disease burden estimation method, we estimated the hospitalization rate of RSV-ALRI among children aged 0~59 months in Suzhou, China. Results: Among 28,209 ALRI cases, 19,317 (68.5%) were tested for RSV and the RSV positive proportion was 21.3% (4,107/19,317). The average hospitalization rate of RSV-ALRI for children aged 0~59 months was 14 (95% confidence interval [CI]:14~14)/1,000 children-years, for children aged 0~5, 6~11, 12~23, and 24~59 months were 70 (95%CI: 67~73), 31 (95%CI: 29~33), 11 (95%CI: 10~12), and 3 (95%CI: 3~3) /1,000 children-years, respectively. Conclusion: There is considerable RSV-ALRI hospitalization among children aged 0~59 months, particularly among children aged <1 years. An effective monoclonal antibody or vaccine is urgently needed to address the substantial hospitalization burden owing to RSV infection. Key words: Respiratory syncytial virus, Hospitalization rate, Acute lower respiratory infection, Children, China

scholarly journals Comparative Analysis of Spatial-temporal Patterns of Human Metapneumovirus and Respiratory Syncytial Virus in Africa Using Genetic Data, 2011-2014

2020 ◽  
Author(s):  
John W Oketch ◽  
Everlyn Kamau ◽  
James R Otieno ◽  
Anthony Mwema ◽  
Clement Lewa ◽  
...  
Keyword(s):  
South Africa ◽  
Respiratory Syncytial Virus ◽  
Southern Africa ◽  
Spatial Clustering ◽  
Temporal Patterns ◽  
Human Metapneumovirus ◽  
Control Measures ◽  
Respiratory Illnesses ◽  
Syncytial Virus ◽  
Viral Sequences

Abstract Background: Human metapneumovirus (HMPV) and respiratory syncytial virus (RSV) are leading causes of viral severe acute respiratory illnesses in childhood. Both the two viruses belong to the Pneumoviridae family and show overlapping clinical, epidemiological and transmission features. However, it is unknown whether these two viruses have similar geographic spread patterns which may provide insight into designing and evaluating their epidemic control measures.Methods: We conducted comparative phylogenetic and phylogeographic analyses to explore the spatial-temporal patterns of HMPV and RSV across Africa using 232 HMPV and 842 RSV attachment (G) glycoprotein gene sequences obtained from 5 countries (The Gambia, Zambia, Mali, South Africa, and Kenya) between August 2011 and January 2014. Results: Phylogeographic analyses found frequently similar patterns of spread of RSV and HMPV. Viral sequences commonly clustered by region, i.e., West Africa (Mali, Gambia), East Africa (Kenya) and Southern Africa (Zambia, South Africa), and similar genotype dominance patterns were observed between neighbouring countries. Both HMPV and RSV country epidemics were characterized by co-circulation of multiple genotypes. Sequences from different African sub-regions (East, West and Southern Africa) fell into separate clusters interspersed with sequences from other countries globally. Conclusion: The spatial clustering patterns of viral sequences and genotype dominance patterns observed in our analysis suggests strong regional links and predominant local transmission. The geographical clustering further suggests independent introduction of HMPV and RSV variants in Africa from the global pool, and local regional diversification.

scholarly journals Using linked health data in international comparisons of infectious disease burden

2018 ◽  
Vol 3 (4) ◽  
Author(s):  
Rachel Reeves
Keyword(s):  
Infectious Disease ◽  
Respiratory Syncytial Virus ◽  
Infectious Diseases ◽  
Disease Burden ◽  
International Comparisons ◽  
Population Level ◽  
Health Data ◽  
Routinely Collected Data ◽  
Syncytial Virus ◽  
International Comparative

Linking population-level health databases – such as those on hospital admissions, GP consultations, prescriptions, maternal and perinatal data, and laboratory data – provides great opportunities to explore the epidemiology and burden of infectious diseases. Furthermore, comparing the epidemiology and burden of infectious diseases on an international scale is crucial in designing and implementing national and global prevention and control measures. However, substantial differences between countries in national health systems (including thresholds for hospital admission), as well as varying availability and quality of routinely collected data, can pose challenges when using linked population-level health databases to compare estimates of infectious disease burden between countries. This session aims to highlight and discuss the opportunities and challenges of international comparisons of infectious disease burden using linked population-level health data. This session will facilitate discussion of the methodological, ethical and resource challenges when using linked health data to produce internationally comparable estimates of the burden of infectious diseases. We will use as an example the ongoing work of the REspiratory Syncytial virus Consortium in Europe (RESCEU) – a large-scale collaborative project producing evidence to inform policymaking and regulatory decisions on novel respiratory syncytial virus (RSV) vaccines and therapeutics. The RESCEU project involves at least seven European countries each using linked routinely collected health data to produce national estimates of the health and economic burden of RSV, by age and risk group, for comparison. The results will highlight target populations for future vaccines and therapeutics, and provide a baseline estimate of the pre-vaccine era burden of disease that can be used to measure future vaccine impact. We will share the challenges faced in the RESCEU project with regards to using linked health data in international comparative work. We will then discuss, with relevance to other ongoing or future projects, how these challenges may be overcome. This session will generate ideas for procedures and tools for international comparative work using routinely collected data to investigate infectious diseases. This session will provide the opportunity to network with other researchers working in this area. We aim to facilitate the generation and dissemination of ideas for current and future projects, and therefore this session is likely to identify areas for potential future international collaborative work.

Sign in / Sign up

Export Citation Format

Share Document